← Back to Search

Other

Hyperbaric Oxygen for Infections (O2B Trial)

Phase 1
Recruiting
Led By Lindell K Weaver, MD
Research Sponsored by Intermountain Health Care, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 30 minutes after chamber session 1
Awards & highlights

O2B Trial Summary

This trial will compare the effects of hyperbaric chamber sessions and normal pressure oxygen breathing on blood neutrophil oxidative burst and cytokine analysis.

O2B Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 30 minutes after chamber session 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 30 minutes after chamber session 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Oxidative Burst Assay

O2B Trial Design

9Treatment groups
Experimental Treatment
Active Control
Group I: Volunteers, normobaric pressureExperimental Treatment1 Intervention
Healthy volunteers will have their blood drawn before and after breathing 100% oxygen at atmospheric pressure (normobaric oxygen) for 120 minutes.
Group II: Hyperbaric chamber inside attendantsExperimental Treatment1 Intervention
Hyperbaric chamber inside attendants will have their blood drawn before, mid-session, and after their chamber exposure during their regular duty day. The hyperbaric chamber exposure will include hyperbaric air and hyperbaric oxygen components (hyperbaric air/oxygen).
Group III: Brain injury research subjectsExperimental Treatment1 Intervention
Research subjects co-enrolled in a study examining hyperbaric oxygen for post-concussive symptoms will have blood drawn before and after their first and fourth hyperbaric chamber sessions.
Group IV: Glucose tolerance testActive Control1 Intervention
Diabetic patients co-enrolled in a hyperbaric oxygen and glucose control study will have blood drawn before and after their glucose tolerance test and their first clinical hyperbaric oxygen treatment.
Group V: Diabetics with active, chronic infectionActive Control1 Intervention
Adult patients with diabetes mellitus and current antibiotic use for active infection will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
Group VI: No diabetes or infectionActive Control1 Intervention
Adult patients without diabetes and not using antibiotics will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
Group VII: Critically ill patients with infectionActive Control1 Intervention
Adult patients with acute, life-threatening infection for which hyperbaric oxygen is clinically indicated will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
Group VIII: Carbon monoxide patientsActive Control1 Intervention
Adult patients with acute carbon monoxide poisoning will have blood drawn before and after their first clinical hyperbaric oxygen treatment.
Group IX: Volunteers, hyperbaric oxygenActive Control1 Intervention
Healthy adult volunteers will have blood drawn before and after a single hyperbaric chamber session.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hyperbaric Oxygen
2005
Completed Phase 3
~260

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Intermountain Health Care, Inc.Lead Sponsor
137 Previous Clinical Trials
1,963,070 Total Patients Enrolled
2 Trials studying Infections
4,050 Patients Enrolled for Infections
Lindell K Weaver, MDPrincipal InvestigatorIntermountain Health Care, Inc.
4 Previous Clinical Trials
212 Total Patients Enrolled

Media Library

Hyperbaric Oxygen (Other) Clinical Trial Eligibility Overview. Trial Name: NCT02563678 — Phase 1
Infections Research Study Groups: Brain injury research subjects, Volunteers, normobaric pressure, Glucose tolerance test, Diabetics with active, chronic infection, No diabetes or infection, Critically ill patients with infection, Carbon monoxide patients, Hyperbaric chamber inside attendants, Volunteers, hyperbaric oxygen
Infections Clinical Trial 2023: Hyperbaric Oxygen Highlights & Side Effects. Trial Name: NCT02563678 — Phase 1
Hyperbaric Oxygen (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02563678 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could I be accepted into this medical investigation?

"To be eligible for the study, participants must have contracted the infection and fall within 18-65 years old. Approximately 40 patients are required to fill out the necessary enrolment forms."

Answered by AI

Are new participants currently being welcomed for this clinical trial?

"This trial is still recruiting participants according to clinicaltrials.gov, and it was initially advertised on April 1st 2015 with an amendment made in August 2nd 2022."

Answered by AI

Does this research project admit participants who have exceeded the age of twenty?

"This clinical trial has established age parameters for enrollment, with a minimum of 18 years old and maximum of 65 years old."

Answered by AI

What is the current number of volunteers enrolled in this research endeavor?

"Affirmative. According to the clinicaltrials.gov record, this medical experiment is now recruiting participants with a post date of April 1st 2015 and an update on August 2nd 2022. The study requires 40 test subjects distributed among two sites."

Answered by AI

Has the Federal Drug Administration sanctioned Hyperbaric Oxygen as a legitimate medical treatment?

"As this is a Phase 1 trial, there are only limited data to support both safety and efficacy; therefore, Hyperbaric Oxygen received a score of 1."

Answered by AI
~4 spots leftby Apr 2025